Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Merck & Company NYSE: MRK-N

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Latest Press Releases

Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day
- CNW Group - Tue Apr 20, 7:00AM CDT
CNW Group - CMTX
Tue Apr 20, 7:00AM CDT
Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day
Animal Healthcare Market Revenue to Cross USD 190 Bn by 2027: Global Market Insights Inc.
- PR Newswire - PRF - Tue Apr 20, 4:00AM CDT
PR Newswire - PRF - CMTX
Tue Apr 20, 4:00AM CDT
, /PRNewswire/ -- According to the latest report , by Global Market Insights Inc., the  will cross by 2027.
South and Central America Organoids Market Analysis & Forecast Report 2021-2027 Featuring STEMCELL Technologies, Thermo Fisher Scientific, Corning Incorporated, Merck -
- BusinessWire - Mon Apr 19, 10:50AM CDT
BusinessWire - CMTX
Mon Apr 19, 10:50AM CDT
The "South and Central America Analysis Organoids Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Application; Source, and Country" report has been added to's offering.
HepaTx appoints Salah Kivlighn as new CEO
- PR Newswire - PRF - Thu Apr 15, 9:00AM CDT
PR Newswire - PRF - CMTX
Thu Apr 15, 9:00AM CDT
, /PRNewswire/ -- HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder , PhD and assume responsibilities on , 2021.
Global Multiple Sclerosis Therapeutics Market to 2027 - COVID-19 Impact and Analysis
- PR Newswire - PRF - Thu Apr 15, 6:45AM CDT
PR Newswire - PRF - CMTX
Thu Apr 15, 6:45AM CDT
, /PRNewswire/ -- The report has been added to offering.
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
- PR Newswire - PRF - Thu Apr 15, 6:00AM CDT
PR Newswire - PRF - CMTX
Thu Apr 15, 6:00AM CDT
, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as MSD outside and , will make to Sutro a milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative therapeutics for cancer and autoimmune disorders. In , Sutro entered into a collaboration with Merck to jointly discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.
Merck to Discontinue Development of MK-7110 for COVID-19
- BusinessWire - Thu Apr 15, 5:46AM CDT
BusinessWire - CMTX
Thu Apr 15, 5:46AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the treatment of hospitalized patients with COVID-19.
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
- BusinessWire - Thu Apr 15, 5:45AM CDT
BusinessWire - CMTX
Thu Apr 15, 5:45AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviral therapeutic. Based on a planned interim analysis of data from the Phase 2, dose-finding portion (Part 1) of two ongoing placebo-controlled Phase 2/3 trials evaluating molnupiravir administered twice a day for five days in outpatients (MOVe-OUT) and hospitalized patients (MOVe-IN) with COVID-19, and from a previously completed Phase 2a dose-ranging study in outpatients, the decision has been made to proceed with the Phase 3 portion (Part 2) of MOVe-OUT in outpatients with COVID-19, evaluating the 800 mg dose of molnupiravir twice daily. Data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in hospitalized patients, who generally had a longer duration of symptoms prior to study entry; therefore, the decision has been made not to proceed to Phase 3.
Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer
- PR Newswire - PRF - Wed Apr 14, 8:00AM CDT
PR Newswire - PRF - CMTX
Wed Apr 14, 8:00AM CDT
and , /PRNewswire/ -- Wugen Inc., a clinical stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies, today announced the appointment of , Ph.D., as the company's Chief Executive Officer.  Dr. Kemp is an accomplished researcher with over 30 publications and built his career at Novartis, Merck and Takeda over 20 years leading pipeline initiatives from early discovery through to the clinic. More recently, he was responsible for transacting Takeda's key strategic partnerships in the CAR-NK and CAR-T cell therapy space.
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
- BusinessWire - Wed Apr 14, 7:00AM CDT
BusinessWire - CMTX
Wed Apr 14, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the funding support of its 20th community-based project in the Safer Childbirth Cities initiative aimed at fostering solutions that will help U.S. cities become safer, more equitable places to give birth. The expansion of the program, launched by Merck for Mothers, Merck's global initiative to help create a world where no woman has to die giving life, comes at an important moment during Black Maternal Health Week occurring April 11 - 17, 2021. The annual week, founded and led by the Black Mamas Matter Alliance, is centered on deepening the conversation and community-led solutions to improve Black maternal health outcomes in the U.S.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies